Aliases & Classifications for Ureter, Cancer of

MalaCards integrated aliases for Ureter, Cancer of:

Name: Ureter, Cancer of 56
Ureter Carcinoma 12 54 15 17 71
Malignant Neoplasm of Ureter 71 32
Ureteral Neoplasms 43 71
Ureter Cancer 12 15
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Ureteral Carcinoma 12
Ureteral Neoplasm 17

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
ureter, cancer of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11819 DOID:4939
OMIM 56 191600
ICD9CM 34 189.2
MeSH 43 D014516
NCIt 49 C7543 C8993
SNOMED-CT 67 363458004
ICD10 32 C66
MedGen 41 C0153619
SNOMED-CT via HPO 68 126882009 263681008
UMLS 71 C0041955 C0153619 C0600079

Summaries for Ureter, Cancer of

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter, Cancer of, also known as ureter carcinoma, is related to ureter adenocarcinoma and transitional cell carcinoma. An important gene associated with Ureter, Cancer of is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Pathways in cancer and Platinum Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include ureter, kidney and lung, and related phenotypes are neoplasm of the ureter and digestive/alimentary

More information from OMIM: 191600

Related Diseases for Ureter, Cancer of

Diseases related to Ureter, Cancer of via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 201, show less)
# Related Disease Score Top Affiliating Genes
1 ureter adenocarcinoma 32.2 KRT7 CEACAM5
2 transitional cell carcinoma 28.9 PLAUR PLAU MSH2 MLH1 KRT7 FGFR3
3 bladder cancer 28.8 TERT PLAUR PLAU NUMA1 MLH1 FGFR3
4 regional ureteric cancer 11.4
5 perforated corneal ulcer 10.5 PLAUR PLAU
6 intratubular embryonal carcinoma 10.4 PLAU KRT7
7 extrahepatic bile duct adenoma 10.4 MSH2 MLH1
8 appendix carcinoid tumor 10.4 MSH2 MLH1
9 familial colorectal cancer 10.4 MSH2 MLH1
10 cervical adenoma malignum 10.4 MSH2 KRT7
11 colorectal cancer, hereditary nonpolyposis, type 6 10.4 MSH2 MLH1
12 jejunal adenocarcinoma 10.3 MLH1 KRT7
13 autosomal dominant non-syndromic intellectual disability 8 10.3 MSH2 MLH1
14 lower lip cancer 10.3 MSH2 MLH1
15 sebaceous gland neoplasm 10.3 MSH2 MLH1
16 sebaceous adenoma 10.3 MSH2 MLH1
17 ileum cancer 10.3 MSH2 KRT7
18 colorectal cancer, hereditary nonpolyposis, type 5 10.3 MSH2 MLH1
19 endometrioid ovary carcinoma 10.3 MSH2 MLH1
20 small intestine adenocarcinoma 10.3 MSH2 MLH1
21 anal fistula 10.3 MSH2 MLH1
22 mixed fibrolamellar hepatocellular carcinoma 10.3 TERT KRT7
23 melanocytic nevus syndrome, congenital 10.3 MSH2 MLH1
24 granulosa cell tumor of the ovary 10.3 TERT KRT7
25 adenomyoma 10.3 MLH1 KRT7
26 dysplastic nevus syndrome 10.2 MSH2 MLH1
27 monophasic synovial sarcoma 10.2 MLH1 KRT7
28 breast-ovarian cancer, familial 1 10.2 MSH2 MLH1
29 urinary tract papillary transitional cell benign neoplasm 10.2 TERT FGFR3
30 bladder papillary transitional cell neoplasm 10.2 TERT FGFR3
31 female reproductive endometrioid cancer 10.2 MSH2 MLH1
32 leukoplakia of penis 10.2 KRT7 CEACAM5
33 urethral villous adenoma 10.2 KRT7 CEACAM5
34 pancreatic foamy gland adenocarcinoma 10.2 KRT7 CEACAM5
35 malignant acrospiroma 10.2 KRT7 CEACAM5
36 mucinous adenofibroma 10.2 KRT7 CEACAM5
37 urinary bladder villous adenoma 10.2 KRT7 CEACAM5
38 cutaneous mucoepidermoid carcinoma 10.2 KRT7 CEACAM5
39 vulva adenocarcinoma 10.2 KRT7 CEACAM5
40 vulval paget's disease 10.2 KRT7 CEACAM5
41 nodular hidradenoma 10.2 KRT7 CEACAM5
42 hidradenoma 10.2 KRT7 CEACAM5
43 cystitis cystica 10.2 KRT7 CEACAM5
44 mucinous intrahepatic cholangiocarcinoma 10.2 KRT7 CEACAM5
45 pancreatic serous cystadenocarcinoma 10.2 KRT7 CEACAM5
46 eccrine adenocarcinoma 10.2 KRT7 CEACAM5
47 renal pelvis adenocarcinoma 10.2 KRT7 CEACAM5
48 external ear carcinoma 10.2 KRT7 CEACAM5
49 anal paget's disease 10.2 KRT7 CEACAM5
50 vaginal tubulovillous adenoma 10.2 KRT7 CEACAM5
51 female urethral cancer 10.2 KRT7 CEACAM5
52 vulvar apocrine adenocarcinoma 10.2 KRT7 CEACAM5
53 renal pelvis transitional cell carcinoma 10.2 MSH2 MLH1 KRT7
54 adenosquamous colon carcinoma 10.2 MSH2 MLH1 KRT7
55 bile duct cystadenocarcinoma 10.2 KRT7 CEACAM5
56 mucinous ovarian cystadenoma 10.2 KRT7 CEACAM5
57 jejunal cancer 10.2 MSH2 MLH1 KRT7
58 acanthoma 10.2 KRT7 FGFR3
59 ovarian cystadenoma 10.2 KRT7 CEACAM5
60 rectosigmoid junction neoplasm 10.2 KRT7 CEACAM5
61 sigmoid neoplasm 10.2 KRT7 CEACAM5
62 krukenberg carcinoma 10.2 KRT7 CEACAM5
63 malignant syringoma 10.2 KRT7 CEACAM5
64 syringoma 10.2 KRT7 CEACAM5
65 biliary papillomatosis 10.2 KRT7 CEACAM5
66 adenoid basal cell carcinoma 10.2 KRT7 CEACAM5
67 appendiceal neoplasm 10.2 KRT7 CEACAM5
68 colonic lymphangioma 10.2 KRT7 CEACAM5
69 squamous cell bile duct carcinoma 10.2 KRT7 CEACAM5
70 bile duct mucoepidermoid carcinoma 10.2 KRT7 CEACAM5
71 appendix adenocarcinoma 10.2 KRT7 CEACAM5
72 clear cell hidradenoma 10.2 KRT7 CEACAM5
73 hidrocystoma 10.1 KRT7 CEACAM5
74 liver sarcoma 10.1 KRT7 CEACAM5
75 benign mesothelioma 10.1 KRT7 CEACAM5
76 pericardium cancer 10.1 KRT7 CEACAM5
77 eccrine sweat gland cancer 10.1 KRT7 CEACAM5
78 biliary tract benign neoplasm 10.1 KRT7 CEACAM5
79 warthin tumor 10.1 KRT7 CEACAM5
80 pancreatic mucinous cystadenoma 10.1 KRT7 CEACAM5
81 ovarian mucinous neoplasm 10.1 KRT7 CEACAM5
82 eccrine acrospiroma 10.1 KRT7 CEACAM5
83 chronic cystitis 10.1 NUMA1 KRT7
84 linitis plastica 10.1 KRT7 CEACAM5
85 eccrine sweat gland neoplasm 10.1 KRT7 CEACAM5
86 sarcomatous intrahepatic cholangiocarcinoma 10.1 KRT7 CEACAM5
87 eccrine porocarcinoma 10.1 KRT7 CEACAM5
88 eccrine papillary adenocarcinoma 10.1 KRT7 CEACAM5
89 cutaneous adenocystic carcinoma 10.1 KRT7 CEACAM5
90 nasal cavity olfactory neuroblastoma 10.1 KRT7 CEACAM5
91 urachal cancer 10.1 TERT CEACAM5
92 non-invasive bladder papillary urothelial neoplasm 10.1 NUMA1 FGFR3
93 uterine body mixed cancer 10.1 MSH2 MLH1
94 urethral benign neoplasm 10.1 KRT7 CEACAM5
95 appendix disease 10.1 KRT7 CEACAM5
96 apocrine sweat gland neoplasm 10.1 KRT7 CEACAM5
97 adenoid squamous cell carcinoma 10.1 KRT7 CEACAM5
98 keratinizing squamous cell carcinoma 10.1 KRT7 CEACAM5
99 bile duct cysts 10.1 KRT7 CEACAM5
100 squamous papillomatosis 10.1 KRT7 CEACAM5
101 gastric diffuse adenocarcinoma 10.1 KRT7 CEACAM5
102 mediastinal cancer 10.1 KRT7 CEACAM5
103 secretory meningioma 10.1 KRT7 CEACAM5
104 clear cell basal cell carcinoma 10.1 KRT7 CEACAM5
105 papillary adenoma 10.1 KRT7 CEACAM5
106 appendix cancer 10.1 KRT7 CEACAM5
107 malignant spiradenoma 10.1 KRT7 CEACAM5
108 esophageal adenosquamous carcinoma 10.1 KRT7 CEACAM5
109 ovarian mucinous adenocarcinoma 10.1 KRT7 CEACAM5
110 benign peritoneal mesothelioma 10.1 KRT7 CEACAM5
111 ovarian clear cell carcinoma 10.1 TERT MLH1 KRT7
112 ovarian benign neoplasm 10.1 KRT7 CEACAM5
113 thyroid angiosarcoma 10.1 TERT CEACAM5
114 ovarian germ cell cancer 10.1 KRT7 CEACAM5
115 li-fraumeni syndrome 10.0 TERT MSH2 MLH1
116 hepatoid adenocarcinoma 10.0 KRT7 CEACAM5
117 borst-jadassohn intraepidermal carcinoma 10.0 KRT7 CEACAM5
118 vulvar disease 10.0 KRT7 CEACAM5
119 klatskin's tumor 10.0 KRT7 CEACAM5
120 sweat gland benign neoplasm 10.0 KRT7 CEACAM5
121 paget disease, extramammary 10.0 KRT7 CEACAM5
122 sebaceous adenocarcinoma 10.0 MSH2 MLH1
123 peritoneum cancer 10.0 KRT7 CEACAM5
124 cholecystolithiasis 10.0 STK10 CEACAM5
125 hydronephrosis 10.0
126 mature teratoma 10.0 KRT7 CEACAM5
127 mucinous cystadenocarcinoma 9.9 KRT7 CEACAM5
128 renal cell carcinoma, papillary, 1 9.9 MSH2 KRT7 FGFR3
129 rectum signet ring adenocarcinoma 9.9 MSH2 MLH1 CEACAM5
130 ascending colon cancer 9.9 MSH2 MLH1 CEACAM5
131 cecum carcinoma 9.9 MSH2 MLH1 CEACAM5
132 colonic benign neoplasm 9.9 MSH2 MLH1 CEACAM5
133 papillary transitional carcinoma 9.9
134 lymphangioma 9.9 MSH2 MLH1 CEACAM5
135 common bile duct disease 9.9 STK10 CEACAM5
136 intestinal benign neoplasm 9.9 MSH2 MLH1 CEACAM5
137 melanoma, cutaneous malignant 1 9.9 TERT MSH2 MLH1
138 transverse colon cancer 9.9 MLH1 KRT7 CEACAM5
139 mucinous adenocarcinoma 9.9 MLH1 KRT7 CEACAM5
140 rectum cancer 9.9 MSH2 MLH1 CEACAM5
141 ovary adenocarcinoma 9.9 MLH1 KRT7 CEACAM5
142 papillary serous adenocarcinoma 9.9 KRT7 CEACAM5
143 ureteral benign neoplasm 9.9
144 cholangiocarcinoma 9.9 TERT KRT7 CEACAM5
145 keratosis, seborrheic 9.8 KRT7 FGFR3 CEACAM5
146 oligodendroglioma 9.8 TERT MSH2 MLH1
147 cell type benign neoplasm 9.8 MLH1 KRT7 CEACAM5
148 ureteral disease 9.8
149 in situ carcinoma 9.8
150 skin benign neoplasm 9.8 MSH2 MLH1 KRT7 FGFR3
151 endocervical carcinoma 9.8 KRT7 CEACAM5
152 colorectal cancer 9.8
153 lymphoma, hodgkin, classic 9.8
154 lymphoma, non-hodgkin, familial 9.8
155 megaloblastic anemia 9.8
156 squamous cell papilloma 9.8
157 squamous cell carcinoma 9.8
158 papilloma 9.8
159 choriocarcinoma 9.8
160 ureter transitional cell carcinoma 9.8
161 alopecia 9.8
162 horseshoe kidney 9.8
163 back pain 9.8
164 teratoma 9.8 KRT7 FGFR3 CEACAM5
165 cecal disease 9.8 STK10 KRT7 CEACAM5
166 adrenocortical carcinoma, hereditary 9.8
167 duodenal atresia 9.8
168 werner syndrome 9.8
169 pulmonary hypertension 9.8
170 adrenal cortical carcinoma 9.8
171 autosomal recessive disease 9.8
172 respiratory failure 9.8
173 pyelonephritis 9.8
174 anuria 9.8
175 bladder disease 9.8
176 adrenal cortical adenocarcinoma 9.8
177 uremia 9.8
178 urinary tract obstruction 9.8
179 kidney disease 9.8
180 cholangitis 9.8
181 premature aging 9.8
182 thrombotic microangiopathy 9.8
183 duodenum adenocarcinoma 9.7 MSH2 MLH1 KRT7 CEACAM5
184 duodenum cancer 9.7 MSH2 MLH1 KRT7 CEACAM5
185 duodenum disease 9.7 MSH2 MLH1 KRT7 CEACAM5
186 signet ring cell adenocarcinoma 9.7 MSH2 MLH1 KRT7 CEACAM5
187 rectum adenocarcinoma 9.7 MSH2 MLH1 KRT7 CEACAM5
188 small intestine cancer 9.7 MSH2 MLH1 KRT7 CEACAM5
189 gastrointestinal system benign neoplasm 9.7 MSH2 MLH1 KRT7 CEACAM5
190 colorectal adenocarcinoma 9.7 MSH2 MLH1 KRT7 CEACAM5
191 pancreatic adenocarcinoma 9.6 TERT PLAUR PLAU MLH1
192 gallbladder cancer 9.6 TERT MLH1 KRT7 CEACAM5
193 choledocholithiasis 9.5 STK10 CEACAM5
194 acute promyelocytic leukemia 9.5 TERT PLAUR PLAU NUMA1
195 adenocarcinoma 9.4 MSH2 MLH1 KRT7 FGFR3 CEACAM5
196 bladder urothelial carcinoma 9.3 TERT NUMA1 MLH1 KRT7 FGFR3
197 esophageal cancer 9.2 TERT PLAUR PLAU MSH2 MLH1 CEACAM5
198 endometrial cancer 9.2 TERT PLAU MSH2 MLH1 KRT7 CEACAM5
199 lung cancer susceptibility 3 9.1 TERT PLAUR PLAU KRT7 FGFR3 CEACAM5
200 pancreatic cancer 9.0 TERT PLAUR PLAU MSH2 MLH1 KRT7
201 gastric adenocarcinoma 9.0 TERT MLH1 KRT7 CEACAM5

Comorbidity relations with Ureter, Cancer of via Phenotypic Disease Network (PDN): (showing 6, show less)


Acute Cystitis Bladder Cancer
Deficiency Anemia Hydronephrosis
Prostatic Hypertrophy Renal Pelvis Carcinoma

Graphical network of the top 20 diseases related to Ureter, Cancer of:



Diseases related to Ureter, Cancer of

Symptoms & Phenotypes for Ureter, Cancer of

Human phenotypes related to Ureter, Cancer of:

31 (showing 1, show less)
# Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 31 HP:0100516

Symptoms via clinical synopsis from OMIM:

56
G U:
cancer of ureter

Clinical features from OMIM:

191600

MGI Mouse Phenotypes related to Ureter, Cancer of:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 FGFR3 MLH1 MSH2 NR6A1 PLAU TERT
2 neoplasm MP:0002006 9.02 FGFR3 MLH1 MSH2 PLAU TERT

Drugs & Therapeutics for Ureter, Cancer of

Drugs for Ureter, Cancer of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 124, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
2
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
6
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
7
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
10
Pembrolizumab Approved Phase 3 1374853-91-4
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
13
Vinblastine Approved Phase 3 865-21-4 241903 13342
14
ramucirumab Approved, Investigational Phase 3 947687-13-0
15
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
16
Bevacizumab Approved, Investigational Phase 3 216974-75-3
17
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
19
Cobalamin Experimental Phase 3 13408-78-1 6857388
20 Antineoplastic Agents, Hormonal Phase 3
21 Vitamin B 12 Phase 3
22 Hormone Antagonists Phase 3
23 Hematinics Phase 3
24 Antiemetics Phase 3
25 Vitamin B12 Phase 3
26 glucocorticoids Phase 3
27 BB 1101 Phase 3
28 Gastrointestinal Agents Phase 3
29 Anti-Inflammatory Agents Phase 3
30 Anti-Infective Agents Phase 2, Phase 3
31 Antiviral Agents Phase 2, Phase 3
32 Immunosuppressive Agents Phase 2, Phase 3
33 Antimetabolites Phase 2, Phase 3
34 Albumin-Bound Paclitaxel Phase 3
35 Vitamin B Complex Phase 2, Phase 3
36 Folic Acid Antagonists Phase 2, Phase 3
37 Folate Phase 2, Phase 3
38 Vitamin B9 Phase 2, Phase 3
39 Dermatologic Agents Phase 2, Phase 3
40 Antirheumatic Agents Phase 2, Phase 3
41
Liposomal doxorubicin Phase 3 31703
42 Mitogens Phase 3
43 Endothelial Growth Factors Phase 3
44 Antineoplastic Agents, Immunological Phase 3
45 Angiogenesis Inhibitors Phase 3
46 Immunoglobulins, Intravenous Phase 3
47 Immunoglobulin G Phase 3
48
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
49
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
50
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
51
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
52
Ifosfamide Approved Phase 2 3778-73-2 3690
53
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
54
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
55
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
56
tannic acid Approved Phase 2 1401-55-4
57
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
58
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
59
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
60
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
61
afatinib Approved Phase 2 439081-18-2, 850140-72-6 10184653
62
Denosumab Approved Phase 2 615258-40-7
63
Fluorouracil Approved Phase 2 51-21-8 3385
64
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
65
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
66
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
67
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
68
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
69
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
70
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
71
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
72
tipifarnib Investigational Phase 2 192185-72-1 159324
73 Piritrexim Investigational Phase 2 72732-56-0
74
Lonafarnib Investigational Phase 2 193275-84-2 148195
75
Rubitecan Investigational Phase 2 91421-42-0
76
Camptothecin Experimental Phase 2 7689-03-4
77 Interleukin-2 Phase 1, Phase 2
78 Pharmaceutical Solutions Phase 2
79 Epothilones Phase 2
80 Epothilone B Phase 2
81 Lactams Phase 2
82 Fluorodeoxyglucose F18 Phase 2
83 Radiopharmaceuticals Phase 2
84
Isophosphamide mustard Phase 2 0
85 topoisomerase I inhibitors Phase 2
86
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
87 Antifungal Agents Phase 1, Phase 2
88 Hormones Phase 2
89 Micronutrients Phase 2
90 Trace Elements Phase 2
91 Vitamins Phase 2
92 Nutrients Phase 2
93 Calcium Supplement Phase 2
94 Calciferol Phase 2
95 Calcium, Dietary Phase 2
96 Alkylating Agents Phase 2
97 Mitomycins Phase 2
98 Antimitotic Agents Phase 2
99 Immunologic Factors Phase 2
100 Tubulin Modulators Phase 2
101 Halichondrin B Phase 2
102 Immunoglobulins Phase 2
103 Antibodies Phase 2
104 Antibodies, Monoclonal Phase 2
105 Protein Kinase Inhibitors Phase 2
106 Prolactin Release-Inhibiting Factors Phase 1, Phase 2
107 Histone Deacetylase Inhibitors Phase 2
108
Calcium Nutraceutical Phase 2 7440-70-2 271
109
Everolimus Approved Phase 1 159351-69-6 70789204 6442177
110
Lapatinib Approved, Investigational Phase 1 231277-92-2, 388082-78-8 208908 9941095
111
Parathyroid hormone Approved, Investigational Phase 1 9002-64-6
112
Lenalidomide Approved Phase 1 191732-72-6 216326
113
Ipilimumab Approved Phase 1 477202-00-9
114
nivolumab Approved Phase 1 946414-94-4
115 Pancreatic Polypeptide Investigational Phase 1 59763-91-6
116
Abexinostat Investigational Phase 1 783355-60-2
117
Veliparib Investigational Phase 1 912444-00-9 11960529
118 Cola Phase 1
119 Liver Extracts Phase 1
120 Adjuvants, Immunologic Phase 1
121 Interleukin-12 Phase 1
122 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
123
Durvalumab Approved, Investigational Early Phase 1 1428935-60-7
124
Tremelimumab Investigational Early Phase 1 745013-59-6

Interventional clinical trials:

(showing 100, show less)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
2 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
3 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
4 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
5 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
6 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation Recruiting NCT03244384 Phase 3
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
8 An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Active, not recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
9 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
10 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
11 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
12 Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
13 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
14 A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer Completed NCT00661609 Phase 2 AZD4877
15 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder Completed NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
16 A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
17 A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
18 A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Completed NCT00101608 Phase 2 vinflunine
19 A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
20 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
21 Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
22 A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis) Completed NCT00112671 Phase 2 sorafenib tosylate
23 A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00006376 Phase 2 chemotherapy;tipifarnib
24 A Phase II Study of Oxaliplatin in Urothelial Cancer Completed NCT00004203 Phase 2 oxaliplatin
25 A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium Completed NCT00021099 Phase 2 ixabepilone
26 A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER Completed NCT00009867 Phase 2 arsenic trioxide
27 A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract Completed NCT00003175 Phase 2 fluorouracil
28 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
29 A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent®) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease Completed NCT00792025 Phase 2 sunitinib malate
30 Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer Completed NCT01031875 Phase 2 pazopanib hydrochloride
31 Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
32 Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997 Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
33 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
34 Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
35 Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
36 Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
37 Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II Completed NCT00014144 Phase 2 gefitinib
38 Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
39 Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00066612 Phase 2 irinotecan hydrochloride
40 A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis) Completed NCT00066352 Phase 2 bortezomib
41 Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
42 A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function. Completed NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
43 A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
44 Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND #61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma Completed NCT00041106 Phase 2 gemcitabine hydrochloride;cisplatin;gefitinib
45 A Phase II Trial Of Adjuvant Chemotherapy For High Risk Transitional Cell Carcinoma Of The Urothelium Completed NCT00028860 Phase 2 carboplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
46 Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00003105 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide;paclitaxel
47 A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
48 A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00310011 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
49 A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy Completed NCT00749892 Phase 2 Erlotinib Hydrochloride
50 A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
51 A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
52 Phase II Study of Genexol-PM, a Cremophor-free, Polymeric Micelle Formulation of Paclitaxel for Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
53 Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
54 Phase I/II Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial Carcinoma Recruiting NCT04004442 Phase 2 Avelumab;AVB-S6-500
55 A Multicenter Randomized Double Blind Study Examining the Efficacy and Safety of Denosumab in Combination With First Line Platinum-based Chemotherapy for Patients With Bone Metastasis Secondary to Metastatic Urothelial Cancer Recruiting NCT03520231 Phase 2 Denosumab;Gemcitabine;Carboplatin;Cisplatin
56 A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer Recruiting NCT03288545 Phase 1, Phase 2 enfortumab vedotin (EV);pembrolizumab;cisplatin;carboplatin;gemcitabine
57 A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03513952 Phase 2 Atezolizumab
58 A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy Active, not recruiting NCT03219333 Phase 2 Enfortumab vedotin
59 Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer Active, not recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
60 LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Active, not recruiting NCT02612194 Phase 2 Crizotinib
61 A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma Active, not recruiting NCT02412670 Phase 2 Methotrexate;Vinblastine;Doxorubicin Hydrochloride;Cisplatin;Gemcitabine Hydrochloride;Carboplatin
62 GEMINI: An Open-Label, Single-Arm, Phase II Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Not yet recruiting NCT04398368 Phase 2 Gemcitabine Hydrochloride
63 A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option Suspended NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
64 A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Terminated NCT00004856 Phase 2
65 A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy Terminated NCT01234519 Phase 1, Phase 2 AEZS-108;AEZS-108 at MTD
66 Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium Terminated NCT00363883 Phase 2 vorinostat
67 Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer Terminated NCT00112905 Phase 2 sorafenib tosylate
68 A Phase II Study of Depsipeptide (NSC-630176) In Patients With Advanced Transitional Cell Carcinoma Of The Urinary Tract Who Have Progressed After Receiving One Prior Chemotherapy Regimen For Advanced Disease Terminated NCT00087295 Phase 2 Depsipeptide
69 Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years) Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
70 Randomized Phase II Trial Of Adjuvant Chemotherapy For Urothelial Carcinoma Comparing GC To Dose-Dense MVAC Withdrawn NCT01639521 Phase 2 cisplatin;gemcitabine hydrochloride;methotrexate;vinblastine;doxorubicin hydrochloride
71 An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Completed NCT02443324 Phase 1 Ramucirumab;Pembrolizumab
72 Phase I Trial of Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Completed NCT01182168 Phase 1 gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
73 Phase I Trial of Dose-Dense Gemcitabine, Doxorubicin, Then Paclitaxel Plus Carboplatin In Patients With Transitional Cell Carcinoma of the Urothelium and Impaired Renal Function Completed NCT00003342 Phase 1 carboplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;paclitaxel
74 Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00003133 Phase 1 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;paclitaxel
75 Phase I Study of Cisplatin, Gemcitabine and Lapatinib as First Line Treatment in Advanced/Metastatic Urothelial Cancer Completed NCT00623064 Phase 1 cisplatin;gemcitabine hydrochloride;lapatinib ditosylate
76 A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Completed NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
77 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
78 An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Completed NCT01844947 Phase 1 Vinflunine;Sorafenib
79 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
80 A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors Completed NCT01352962 Phase 1 Gemcitabine;Carboplatin;Lenalidomide
81 Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer Recruiting NCT02437370 Phase 1 Pembrolizumab;Docetaxel;Gemcitabine Hydrochloride
82 A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting NCT03590054 Phase 1 Abexinostat
83 A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib;Cabozantinib S-malate
84 Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer Terminated NCT01282333 Phase 1 gemcitabine hydrochloride;veliparib;cisplatin
85 A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands Unknown status NCT00757614
86 A Clinical Study of the Living-related Renal Transplantation With Restored Kidneys (Interventional Trial) Unknown status NCT00994188
87 A Randomized Trial of a Family Caregiver Palliative Care Intervention Completed NCT01846520
88 BARC: A Secreted Marker of Kidney Cancer Completed NCT00900276
89 A Prospective In-Vivo Human Pilot Study to Assess Confocal Laser Endomicroscopy Characteristics of Upper Tract Urothelial Carcinoma Completed NCT03013920
90 Remote Post-Operative Rounding and the Physician Ability to Identify Morbidity Completed NCT00263107
91 Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial Recruiting NCT02430779
92 Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter Recruiting NCT02607709
93 Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA Recruiting NCT04197414
94 A Genotype-Phenotype Urothelial Cancer Registry Recruiting NCT00902590
95 Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB) Recruiting NCT03291028
96 Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy Recruiting NCT01050504
97 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
98 A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy Active, not recruiting NCT02812420 Early Phase 1
99 UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217 Active, not recruiting NCT02643043
100 The Master Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Systemic Treatment (T)

Search NIH Clinical Center for Ureter, Cancer of

Inferred drug relations via UMLS 71 / NDF-RT 50 :


pembrolizumab

Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter, Cancer of

Anatomical Context for Ureter, Cancer of

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter, Cancer of:

19
Ureter

MalaCards organs/tissues related to Ureter, Cancer of:

40
Kidney, Lung, Testes, Bone, Liver, Endothelial

Publications for Ureter, Cancer of

Articles related to Ureter, Cancer of:

(showing 32, show less)
# Title Authors PMID Year
1
Familial occurrence of carcinoma of the ureter. 56
5923294 1966
2
[Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma]. 54 61
15191676 2004
3
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]. 61 54
14981816 2004
4
Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 27 cases. 61
29370814 2018
5
[PRIMARY SMALL CELL NEUROENDOCRINE CARCINOMA OF THE URETER]. 61
30662049 2018
6
[Port-Site Metastasis of an Urothelial Carcinoma after Laparoscopic Nephroureterectomy : A Case Report]. 61
29103252 2017
7
[Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 24 cases]. 61
28355757 2017
8
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review. 61
27765044 2016
9
The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients. 61
27029078 2016
10
Comprehensive data analysis of human ureter proteome. 61
26937461 2016
11
[Port-Site Metastasis of Urothelial Carcinoma after Laparoscopic Nephroureterectomy: A Case Report]. 61
27018412 2016
12
A proteomic glimpse into human ureter proteome. 61
26442468 2016
13
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. 61
25474136 2014
14
Pulmonary tumor thrombotic microangiopathy induced by ureteral carcinoma: a necropsy case report. 61
25298767 2014
15
The impact of real-time 3d imaging by ultra-high speed optical coherence tomography in urothelial carcinoma. 61
24289823 2013
16
Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. 61
18379418 2008
17
In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein prefractionation in combination with liquid chromatography-tandem mass spectrometry. 61
17711322 2007
18
[Ureter cancer of complete double renal pelvis and ureter: a case report]. 61
12613013 2002
19
Triplicity of the malignant tumor of the urinary bladder. 61
8711348 1994
20
[Urothelial cancer of the upper urinary tract]. 61
8372411 1993
21
In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity. 61
8483327 1993
22
[A study on cathepsin B-like substance in patients with urological cancer]. 61
8464189 1993
23
[Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ]. 61
1481770 1992
24
Comparison of radiation sensitivity for three cell lines as measured by the cloning assay and the micro-nucleus test. 61
2260014 1990
25
Analysis of cell survival after multiple fractions per day and low-dose-rate irradiation of two in vitro cultured rat tumor cell lines. 61
4048393 1985
26
[Phase II study of cis-diamminedichloroplatinum (II) in genitourinary cancer]. 61
6764107 1982
27
[An organ-preserving operation in primary ureteral cancer]. 61
7210928 1980
28
Thermal enhancement of the effectiveness of gamma radiation for induction of reproductive death in cultured mammalian cells. 61
309451 1978
29
Comparison of three mammalian cell-lines with respect to their sensitivities to hyperthermia, gamma-rays and U.V.-radiation. 61
301514 1977
30
[Papillary ureter carcinoma as a recurrence of renal pelvis tumor after nephrectomy; diagnosis and therapy]. 61
13399291 1956
31
[Primary ureter carcinoma]. 61
14380939 1955
32
[Case report of a metastatic ureter carcinoma]. 61
14397652 1955

Variations for Ureter, Cancer of

Expression for Ureter, Cancer of

Search GEO for disease gene expression data for Ureter, Cancer of.

Pathways for Ureter, Cancer of

Pathways related to Ureter, Cancer of according to GeneCards Suite gene sharing:

(showing 3, show less)
# Super pathways Score Top Affiliating Genes
1 12.18 TERT MSH2 MLH1 FGFR3
2 10.42 MSH2 MLH1
3 9.74 PLAUR PLAU

GO Terms for Ureter, Cancer of

Cellular components related to Ureter, Cancer of according to GeneCards Suite gene sharing:

(showing 3, show less)
# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.46 TERT NUMA1 MSH2 MLH1
2 mismatch repair complex GO:0032300 8.96 MSH2 MLH1
3 specific granule membrane GO:0035579 8.8 STK10 PLAUR PLAU

Biological processes related to Ureter, Cancer of according to GeneCards Suite gene sharing:

(showing 7, show less)
# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 9.4 PLAUR PLAU
2 isotype switching GO:0045190 9.37 MSH2 MLH1
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.32 MSH2 MLH1
4 positive regulation of isotype switching to IgG isotypes GO:0048304 9.26 MSH2 MLH1
5 positive regulation of isotype switching to IgA isotypes GO:0048298 9.16 MSH2 MLH1
6 somatic recombination of immunoglobulin gene segments GO:0016447 8.96 MSH2 MLH1
7 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MSH2 MLH1

Molecular functions related to Ureter, Cancer of according to GeneCards Suite gene sharing:

(showing 4, show less)
# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 9.43 TERT NUMA1 MSH2
2 protein homodimerization activity GO:0042803 9.35 TERT STK10 NR6A1 MSH2 CEACAM5
3 mismatched DNA binding GO:0030983 9.16 MSH2 MLH1
4 guanine/thymine mispair binding GO:0032137 8.62 MSH2 MLH1

Sources for Ureter, Cancer of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....